1.
Bioorg Med Chem Lett
; 14(10): 2469-72, 2004 May 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15109634
RESUMO
Incorporation of an SRI (serotonin reuptake inhibitor) pharmacophore into a selective 5-HT(1D) agonist has led to the discovery of a molecule having both 5-HT(1D) antagonist and SRI activity. RPS methodology was used to develop the SAR and identify potential approaches to reduce unwanted adrenergic alpha 1 and dopamine D(2) cross-reactivities.